NASDAQ
0.51USD
-0.02 (-3.72%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.2M
P/E
—
EPS
—
Beta
-1.05
52W range
0.507-13.5
Day range
0.51–0.53
Open
0.53
Prev close
0.53
Volume
528K
Avg volume
381.6K
Dividend
0.00
IPO
2022-09-01
https://seekingalpha.com/article/4923990-bioaffinity-technologies-inc-biaf-discusses-innovations-in-lung-cancer-screening-technologies · 7/22/2026+0.60
https://www.businesswire.com/news/home/20260707410622/en/bioAffinity-Technologies%E2%80%99-Quarterly-CyPath%C2%AE-Lung-Sales-Double-to-New-Record-as-Commercial-Momentum-Continues/ · 7/7/2026+1.00
https://seekingalpha.com/article/4915519-bioaffinity-technologies-inc-biaf-discusses-noninvasive-testing-and-risk-stratification-for · 6/17/2026+0.20
https://www.zacks.com/stock/news/2901533/bioaffinity-stock-surges-113-8-in-3-months-what-s-driving-the-rally · 4/16/2026+0.60
https://seekingalpha.com/article/4889381-bioaffinity-technologies-inc-biaf-discusses-clinical-integration-of-cypath-lung-in-pulmonary · 4/9/2026+0.80
https://www.defenseworld.net/2025/12/27/bioaffinity-technologies-nasdaqbiaf-stock-price-down-4-9-heres-what-happened.html · 12/27/2025-0.40
https://www.zacks.com/stock/news/2793210/biaf-stock-dips-after-q3-earnings-reflect-lower-sales-and-wider-loss?cid=CS-STOCKNEWSAPI-FT-microcap_article|earnings-2793210 · 11/19/2025-0.60
https://www.businesswire.com/news/home/20250930472506/en/bioAffinity-Technologies-Announces-Closing-of-4.8-Million-Public-Offering/ · 9/30/2025+0.50
https://www.benzinga.com/trading-ideas/movers/25/09/47938693/energy-fuels-firefly-aerospace-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session · 9/30/2025-0.50
https://www.businesswire.com/news/home/20250926999689/en/bioAffinity-Technologies-Adds-to-Growing-Number-of-Case-Studies-Demonstrating-Clinical-Value-of-CyPath%C2%AE-Lung/ · 9/26/2025+0.80
https://www.businesswire.com/news/home/20250814188245/en/bioAffinity-Technologies-Announces-Closing-of-Private-Placement-and-Warrant-Inducement-Transaction-for-Approximately-1.2-Million-in-Gross-Proceeds/ · 8/14/2025+0.50
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
